# OnCo record ferdinandos-skoulidis (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/ferdinandos-skoulidis/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "ferdinandos-skoulidis" ;
  schema:name "Ferdinandos Skoulidis"@en ;
  schema:description "Led CodeBreaK 100, the trial that made sotorasib the first approved KRAS inhibitor, and showed STK11/KEAP1 co-mutations blunt immunotherapy."@en ;
  schema:url <https://onco.cc/people/ferdinandos-skoulidis/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Skoulidis%20F%5BAuthor%5D%20KRAS> ;
  onco:tag "lung", "kras", "targeted-therapy" ;
  schema:jobTitle "Associate Professor of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/> ;
  onco:institutions <https://onco.cc/institutions/md-anderson/> ;
  onco:trials <https://onco.cc/trials/codebreak-200/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-codebreak-200-lancet-2023/>, <https://onco.cc/key-papers/paper-ostrem-kras-g12c-nature-2013/> ;
  schema:affiliation <https://onco.cc/institutions/md-anderson/> .